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ABSTRACT  25 
Staphylococcus aureus (MRSA) resistant to decolonization agents such as mupirocin 26 
and chlorhexidine increase the need to develop alternative decolonization molecules. 27 
The absence of reported adverse reactions and bacterial resistance to polyhexanide 28 
makes it an excellent choice as topical antiseptic. In the present study we evaluated the 29 
in vitro and in vivo capacity to generate strains with reduced polyhexanide susceptibility 30 
and cross-resistance with chlorhexidine and/or antibiotics currently used in clinic. Here 31 
we report the in vitro emergence of reduced-susceptibility to polyhexanide by 32 
prolonged-stepwise exposure to low concentrations in broth culture. Reduced 33 
susceptibility to polyhexanide was associated with genomic changes in the mprF and 34 
purR genes, and with concomitant decreased susceptibility to daptomycin and other 35 
cell-wall active antibiotics. However, the in vitro emergence of reduced-susceptibility to 36 
polyhexanide did not result in cross-resistance to chlorhexidine antiseptic. During in 37 
vivo polyhexanide clinical decolonization treatment, neither polyhexanide reduced-38 
susceptibility nor chlorhexidine cross-resistance were observed. Together, these 39 
observations suggest that polyhexanide could be used safely for decolonisation of 40 
carriers of chlorhexidine-resistant S. aureus strains but highlight the need for careful use 41 
of polyhexanide at low antiseptic concentrations.  42 
  43 
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INTRODUCTION 44 
Prevention of healthcare-associated infections includes the use of antiseptic 45 
agents. Chlorhexidine antiseptic solution is one of the most widely used antiseptics 46 
since the 1950s and is administered for hand and skin disinfection prior to surgical 47 
intervention, bathing patients in intensive care units, decolonization of carriers of 48 
methicillin-resistant Staphylococcus aureus (MRSA) and prevention of vascular 49 
catheter infections (1). Broad range and long residual activity, safety and good tolerance 50 
are key advantages of this antiseptic agent. However, chlorhexidine reduced-51 
susceptibility associated with biocide-efflux pumps (1, 2) has shown to impact clinical 52 
outcomes (3, 4). 53 
Increasing chlorhexidine reduced-susceptibility due to its intensive clinical use (5) 54 
has led to the development of new antiseptics such as polyhexanide (polyhexamethylene 55 
biguanide). This antiseptic was originally developed as a surface disinfectant but, in the 56 
early 1990s, was introduced in medicine for local antiseptic treatment (6) and is 57 
currently used in the United States for wound disinfection. Polyhexanide shows good 58 
safety, tissue compatibility and reduction of bacterial load and infection rate of chronic 59 
and burn wounds, and is proposed as an alternative to topical antibiotic treatment (7, 8). 60 
Polyhexanide is a cationic polymer attaching primarily to negatively charged 61 
membrane phospholipids, interfering with its stability and leading to membrane 62 
permeability. Lipopolysaccharides and teichoic acids, from Gram-negative and Gram-63 
positive bacteria respectively, and peptidoglycan components of the cell wall were also 64 
identified as polyhexanide targets (9-11). Accordingly, polyhexanide was shown to 65 
have potent antimicrobial activity against both Gram-positive and Gram-negative 66 
bacteria (8, 12). In contrast to other antiseptics, reduced susceptibility of polyhexanide 67 
and its association with antibiotic resistance has not yet been detected (12-16). Another 68 
exceptional characteristic recently identified for polyhexanide is its intracellular 69 
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bactericidal activity recognized as an important property to potentially treat skin 70 
infections caused by intracellular bacteria (17). 71 
The lack of reported adverse reactions, selection of bacterial resistance, 72 
antagonisms with antibiotic activities and its potential use as an intracellular bactericidal 73 
agent makes polyhexanide an excellent choice as topical antiseptic to prevent and treat 74 
bacterial infections. To test polyhexanide, we previously assessed its efficacy to 75 
eradicate MRSA carriage in vivo by a randomized placebo-controlled clinical trial (18), 76 
which showed that single polyhexanide decolonization course was not sufficient to 77 
significantly eradicate MRSA carriage (18).  78 
In the current microbiological study we analyzed the potential reasons that could 79 
explain low polyhexanide decolonization rates in vivo. We tested the in vitro emergence 80 
of polyhexanide resistance, the potential cross-resistance with chlorhexidine antiseptic 81 
and identified the genetic mutations potentially leading to reduced susceptibility to 82 
polyhexanide.  83 
 84 
RESULTS 85 
In vitro emergence of polyhexanide reduced-susceptibility and cross-86 
resistance with chlorhexidine. To analyze the potential emergence of polyhexanide 87 
reduced-susceptibility in vitro, we selected three different clinical MRSA strains (COL, 88 
134947 and 128822) that were subjected to a stepwise training method in polyhexanide 89 
broth cultures (see materials and methods). As shown in Table 1, after several passages 90 
of 2 days each on increasing concentrations of polyhexanide, two out of three MRSA 91 
strains (with an initial polyhexanide MIC of 0.5 and 1 µg/ml) ultimately grew at 92 
polyhexanide concentrations of 2, 4 and 8 µg/ml (Table 1). Prolonged exposure did not 93 
increase further the levels of polyhexanide MIC.  94 
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To further analyze cross-resistance development, we assessed the emergence of 95 
chlorhexidine reduced-susceptibility in vitro, using the same methodology as described 96 
above for polyhexanide. After several passages of 2 days each on chlorhexidine, again 97 
two out of three MRSA strains (with an initial chlorhexidine MIC of 2 and 4 µg/ml) 98 
ultimately grew at a chlorhexidine concentration of 8 µg/ml (Table 1). Emergence of 99 
chlorhexidine reduced-susceptibility was not accompanied by changes in polyhexanide 100 
MIC (Table 1). Similarly, emergence of polyhexanide reduced-susceptibility was not 101 
accompanied by changes in chlorhexidine MIC, suggesting an absence of cross-102 
resistance between these antiseptics.  103 
 104 
Antibiotic susceptibility profiles and genomic sequencing of MRSA strains 105 
with reduced susceptibility to antiseptics. Previous studies have shown an association 106 
of chlorhexidine resistance with resistance to antibiotics (19). To determine whether in 107 
vitro emergence of reduced susceptibility to polyhexanide or chlorhexidine in our 108 
strains is associated with emergence to antibiotic resistance, we analyzed the antibiotic 109 
susceptibility pattern of each parental isolate and its cognate in vitro derived 110 
polyhexanide - or chlorhexidine-exposed derivative showing altered susceptibility 111 
(COL/COLP3/COLP5, 134947/134947P6, 128822/128822P6, COL/COLP7/COLP10, 112 
134947/134947P10, 128822/128822P6). Antibiotic disc diffusion and Etest assays 113 
showed that reduced-susceptibility to polyhexanide was accompanied by changes in 114 
antibiotic susceptibility profiles (vancomycin, teicoplanin, daptomycin) as compared to 115 
the parental strains (Table 2). Interestingly, strains showing reduced susceptibility to 116 
polyhexanide showed reduced susceptibility to daptomycin with or without concomitant 117 
alteration susceptibility to vancomycin or teicoplanin. In contrast to polyhexanide, no 118 
consistent association between reduced susceptibility to chlorhexidine and antibiotic 119 
resistance was observed; of three strains with reduced chlorhexidine susceptibility, only 120 
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one showed an association with reduced ciprofloxacin susceptibility, in agreement with 121 
previous observations (20). In a single background (MRSA128822) showing high initial 122 
MIC level against chlorhexidine (MIC = 8µg/ml), we observed reduced susceptibility to 123 
daptomycin (Table 2). 124 
To identify genomic changes associated with antiseptic/antibiotic reduced-125 
susceptibility, we performed de novo whole-genome sequencing (see materials and 126 
methods). Using Illumina-Solexa technology, we obtained between 4Õ107Õ708 and 127 
3Õ452Õ730 of 300-bp paired-end reads for all strains leading to between 140X and 287X 128 
of coverage depth after quality filtering. Genome assembly results in 2Õ821Õ361-bp for 129 
the S. aureus COL strain, 2Õ794Õ034-bp for S. aureus SA134947 and 2Õ922Õ225-bp for 130 
MRSA128822. After quality assessment, filtering and genome assembly, single 131 
nucleotide polymorphisms, insertions and deletions were identified between antiseptic-132 
selected mutants and their cognate parents. As shown in Table 2, antiseptic-selected 133 
mutants showing changes in polyhexanide or chlorhexidine MICs possessed mutations 134 
in mprF purR, mepA, pldB, glpD genes and in some intergenic regions near norA, ndrL 135 
or other hypothetical genes. Interestingly, these genes affect lipid metabolism (mprF, 136 
pldB and glpD) or are already known to affect resistance to chlorhexidine (MepA efflux 137 
pump) (20) or to daptomycin (21) and nisin cationic antimicrobial peptide antibiotics 138 
(22) (MprF protein and PurR transcriptional activator, respectively). To establish the 139 
contribution of the observed purR mutation to polyhexanide resistance, the MIC of 140 
polyhexanide was determined against S. aureus SH1000:purR T686G, the construction 141 
of which is described elsewhere (22). No change in polyhexanide susceptibility was 142 
observed when compared with parental SH1000 or COL, suggesting that this mutation 143 
does not contribute to the observed resistance phenotype. Given that nonsynonymous 144 
mprF mutations were identified (Table 1) in all strains displaying polyhexanide 145 
resistance, it seems likely that these mutations are responsible for resistance. MIC 146 
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determination was also assessed in strains harboring mprFC884T identified in a 147 
different experimental context (23). This mutation leading to daptomycin resistance was 148 
responsible for a 2-fold factor increase in polihexanide (from 4 to 8 µg/ml). Note that 149 
we tried several times but we failed to transfer individual mutation into the parental 150 
strain COL, by transduction using several staphylococcal phages.  151 
Polyhexanide and chlorhexidine susceptibility profiles of MRSA isolates 152 
before and after polyhexanide decolonization. Our previous published study 153 
suggested a limited efficacy of a single polyhexanide decolonization course in 154 
eradicating MRSA carriage (18). Despite several possible limitations of our study, one 155 
possible explanation was the emergence of resistance to polyhexanide or cross-156 
resistance between chlorhexidine and polyhexanide antiseptics. Indeed, we previously 157 
reported that resistance to chlorhexidine in our hospital was associated with the 158 
dominant clone, the South German SCCmecI ST type 228 MRSA (3). To monitor 159 
potential polyhexanide and chlorhexidine reduced-susceptibility in our strain collection, 160 
we selected nasal MRSA strains isolated before (D0) and after active polyhexanide 161 
decolonization treatment (D28) (Tables 3 and 4). MLVA analysis was performed to 162 
confirm the clonal relationship between D0 and D28 bacterial strains isolated from the 163 
same patient and to deduce the ST-type of our strain collection (not shown). All selected 164 
pairs of strains isolated from the same patients were indeed clonally related and showed 165 
ST 228 (n=20), ST5 (n=2), ST8 (n=2), ST105 or ST22 (n=1).  166 
Reduced susceptibility to polyhexanide and chlorhexidine was further measured 167 
using macrodilution minimal inhibitory concentration (MIC) method. Our strain 168 
collection shows polyhexanide and chlorhexidine MIC ranging between 0.25-1 µg/ml 169 
and 0.5-4 µg/ml, respectively, with a modal polyhexanide MIC of 0.5 µg/ml and of 170 
chlorhexidine MIC of 4 µg/ml (Table 3). According to the epidemiological cut-off value 171 
proposed by Fabry et al, our S. aureus collection is considered susceptible to 172 
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polyhexanide and 50% resistant to chlorhexidine (15). However, no correlation between 173 
chlorhexidine and polihexanide susceptible profiles or cross-resistance was observed. 174 
Moreover, the majority of our D28 isolates showed neither polihexanide nor 175 
chlorhexidine MIC changes compared to isolates at D0. Altogether, our results suggest 176 
that the limited MRSA decolonization rate previously observed (18, 17) is not related to 177 
the presence or selection of strains with reduced-susceptibility to polyhexanide nor with 178 
cross-resistance towards chlorhexidine. 179 
 180 
 181 
DISCUSSION 182 
This study focused on the development of polyhexanide reduced-susceptibility 183 
and emergence of cross-resistance with other antiseptics or antibiotics in various MRSA 184 
strains. We previously found that a single polyhexanide decolonization course was not 185 
fully effective in eradicating MRSA carriage (18). This study performed in a population 186 
mainly composed of MRSA harboring qac genes excludes the possibility that the 187 
moderate decolonization rate of MRSA relies on the emergence of isolates showing 188 
polyhexanide reduced-susceptibility or on potential cross-resistance between 189 
polyhexanide and chlorhexidine in MRSA.  190 
In the present study, we provide evidence that prolonged in vitro exposure to low 191 
levels of polyhexanide results in the emergence of polyhexanide reduced-susceptibility 192 
in MRSA without cross-resistance to chlorhexidine. Moreover, we repeatedly observed 193 
concomitant changes in resistant profiles of daptomycin and glycopeptides, antibiotics 194 
used for S. aureus clinical treatment. This observation should encouraged further in vivo 195 
studies, as various local and low disinfectant concentrations can potentially be found 196 
after topical administration of this substance or also found at residual levels on surfaces 197 
(15, 24). 198 
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In vitro, we detected polyhexanide reduced-susceptibility (MIC changes from 199 
0.5 to 4 µg/ml) following step-wise and prolonged (2 days) passages in low 200 
concentrations of polyhexanide (< 2 µg/ml of polyhexanide). The occurrence of 201 
polyhexanide reduced-susceptibility under low concentrations in vitro does not argue 202 
against the general use of polyhexanide for decolonization, because the high therapeutic 203 
concentration used, will highly exceed the low concentrations that permit resistance 204 
development and will rapidly eradicate bacteria. However, it suggests careful follow-up 205 
of resistance profiles during topical administration.  206 
To understand the molecular pathways leading to polyhexanide reduced-207 
susceptibility, we performed whole genome sequencing and identified genetic changes 208 
in strains selected in vitro under polyhexanide exposition compared to wild-type strains. 209 
Mutations were found in mprF genes that can be correlated with polyhexanide reduced-210 
susceptibility. Indeed, polyhexanide is a cationic polymer attaching to negatively 211 
charged molecules and acting on bacterial membrane phospholipids, 212 
lipopolysaccharides, teichoic acids and peptidoglycan components of cell wall (9, 10). 213 
The integral membrane protein MprF, lysinylate membrane lipid phosphatidyl glycerol 214 
(PG) and subsequently flips lysyl phosphatidyl glycerol (L-PG) to the outer leaflet of 215 
the plasma membrane (21). The mprF mutations detected in our strains may potentially 216 
increase L-PG synthesis and flipping leading to increase of membrane positive surface 217 
charge and consequently charge repulsion for cationic molecules, such as polyhexanide. 218 
Interestingly, our mutants showing mprF mutations and reduced susceptibility to 219 
polyhexanide also show resistance to the cationic antibiotic daptomycin. The identified 220 
mprF mutation L337S is located in the so-called bifunctional domain of mprF known to 221 
be a hot spot of mprF mutations leading to daptomycin resistance (25). Further studies 222 
are underway to highlight the association of mprF mutations and antiseptic resistance, a 223 
mechanism that to our knowledge has not been previously identified. Regarding purR 224 
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mutations, further studies are needed to understand the mechanistic link between purR 225 
mutations and reduced-susceptibility to polyhexanide. In addition to containing the 226 
mprF mutation described above, a polyhexanide-resistant mutant of 134947 (P6) was 227 
found to contain a non-synonymous mutation in purR. This mutation has been 228 
encountered elsewhere when selecting for resistance to the lantibiotic nisin (22), and 229 
other purR mutations were discovered in mutants displaying resistance to vancomycin 230 
(26). However, the observed purR mutations had no apparent role in nisin or 231 
vancomycin resistance (22, 26). This also seems to be the case in polyhexanide 232 
resistance, as an SH1000 strain containing PurR(V229G) was no more resistant to 233 
polyhexanide as its parent. It is not clear why mutations in purR emerge when selecting 234 
for resistance to antibiotics or antiseptics, however it is apparent that they are not 235 
required to confer resistance to these agents. 236 
An important observation of this study is the potential emergence of cross-237 
resistance between antiseptics and antibiotics used in clinical routine. This has been 238 
observed for antiseptics such as chlorhexidine or triclosan in other bacterial species (27-239 
29). In S. aureus, cross-resistance between antiseptics and antibiotics was previously 240 
observed after chlorhexidine exposure selecting for resistance to several E-lactam 241 
antibiotics (30). To date, a single study assessed and found no correlation between 242 
polyhexanide and antibiotic resistant profiles. However, the analyzed collection lacks 243 
polyhexanide reduced-susceptible isolates, which prevents any conclusion on cross-244 
resistance between these molecules (15). Our results showed that development of 245 
reduced-susceptibility to polyhexanide can be accompanied by changes in resistance to 246 
not only daptomycin but cell-wall active antibiotics such as vancomycin and 247 
teicoplanin. This can be expected if taking into account the mode of action of 248 
polyhexanide. Any molecular change leading to alteration in cell wall could potentially 249 
affect the net charge of cell wall and indirectly affect polyhexanide binding. This link 250 
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was reliably observed in independent experiments and in different bacterial genetic 251 
backgrounds. However, we did not observe the development of polyhexanide reduced-252 
susceptibility accompanied always by an identical antibiotic resistant pattern, even 253 
though identical genetic mutations were identified. Studies related to whole 254 
transcriptomic would probably contribute to clarify the mechanisms leading to 255 
alteration of susceptibility. 256 
Our experiments were performed in vitro which appears as the main limitation. In 257 
a recent clinical trials dedicated to assess the decolonisation efficacy of polyhexanide 258 
(18), we were able to collect 27 pairs of MRSA resulting from cases of decolonization 259 
failure. No significant MIC alterations for antibiotics were observed between pairs of 260 
isolates in this small collection following polyhexanide exposition. Note however that 261 
in vivo, bacteria are probably exposed to the concentrations used in our report at specific 262 
body sites and that our design mimicking potential prolonged or repeated exposition to 263 
antimicrobial solutions may reflect the in vivo situation. In these conditions, we reliably 264 
obtained alteration of susceptibility to the polyhexanide as well as alteration in the 265 
MRSA antibiotic susceptibility profiles, which is a potential risk of emergence of 266 
antibiotic resistances, particularly in area showing generalized and extensive utilization 267 
of antiseptic solutions. 268 
269 
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MATERIALS AND METHODS 270 
Bacterial strains. Bacterial strains used in this study are listed in Tables 3 and 4. 271 
Strains COL, 134947 and 128822 are MRSA strains belonging to different ST types and 272 
used to analyze phenotypic and genetic alterations following exposure to antiseptic 273 
solutions. The other MRSA isolates were collected from a previously published 274 
randomized, placebo-controlled trial, assessing the clinical efficacy of polyhexanide in 275 
eradicating MRSA carriage at day 28 (D28) after decolonization (18). Briefly, selected 276 
MRSA-colonized patients fulfilling inclusion criteria were randomized to receive either 277 
active treatment or placebo for 10 days. Active treatment (Prontoderm
¨
Gel light 278 
solution containing polyhexanide 20% in a base of Glycerine 99% and 279 
Hydroxyethylcellulose; B. Braun Medical AG, Sempach, Switzerland) was applied 280 
intranasally three times a day to the anterior nares. At D28, swabs were taken from 281 
nares and identification of MRSA was performed as previously described (18). MRSA 282 
strains before (D0) and after treatment (D28) were saved frozen in skimmed milk for 283 
further determinations.  284 
Molecular MRSA typing. MRSA isolates were subjected to a rapid genotyping 285 
assay using Multiple-Locus Variable Number of Tandem Repeats Analysis (MLVA) 286 
assay. Briefly, this assay is based on a multiplex PCR using ten primer pairs targeting 9 287 
genes showing variable numbers of tandem repeats and an additional pair of primers 288 
allowing amplification of the mecA gene as internal control. This method shows 289 
discriminatory power that is at least similar to that of pulsed-field gel electrophoresis 290 
(31). The analysis was performed on isolated colonies grown on MuellerÐHinton agar 291 
disrupted by vortex agitation. PCR amplification was then evaluated using a micro 292 
capillary electrophoresis system (2100 Bioanalyzer, Agilent Technologies) and 293 
automatically analyzed using specifically developed software (31). The genotype of 294 
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each strain was deduced by comparison with profiles obtained with characterized 295 
control isolates (31). 296 
Polyhexanide susceptibility testing. Polyhexanide 20% solution was obtained 297 
and prepared as recommended by the manufacturer. The stock solution was diluted in 298 
the test broth to final polyhexanide concentrations of 0.25, 0.5, 1, 2 and 4 µg/ml. 299 
polyhexanide minimum inhibitory concentration (MIC) was determined as previously 300 
described (8) but using a macrodilution method. Briefly, one bacterial colony growing 301 
on Mueller-Hinton agar was used to inoculate 1 ml of Mueller-Hinton broth. Overnight 302 
culture at 37¡C was diluted to deliver the final inoculum of 1.5 x 10
6
 CFU/ml into each 303 
tube containing different polyhexanide concentrations (MHB containing 0, 0.25, 0.5, 1, 304 
2 and 4 µg/ml of polyhexanide ). After incubation for 24-48h at 37¡C, MIC was defined 305 
as the lowest concentration allowing bacterial growth. Three independent MIC 306 
determinations were performed for each isolate. Modal MICs for each isolate are 307 
represented. Chlorhexidine MIC was determined as described above but using 308 
chlorhexidine diluted to a final concentration of 0.12-16 µg/ml. 309 
In vitro selection of polyhexanide and chlorhexidine mutants with reduced 310 
susceptibility. The selected MRSA strains COL, MRSA134947 and MRSA128822 311 
showing an initial polyhexanide MIC = 0.5, 1 and 1 µg/ml, respectively, were serially 312 
passaged onto increasing concentrations of polyhexanide. Briefly, 100 ml of Muller 313 
Hinton Broth (CAMHB) containing MIC concentration (0.5 or 1 µg/ml) of 314 
polyhexanide was inoculated with overnight bacteria at a concentration of 1 x 10
9
 315 
bacteria/ml. After incubation for 2 days at 37¡C, bacteria growing at concentration of 316 
polyhexanide 0.5 or 1 µg/ml, were used for a second step passage in increased 317 
polyhexanide concentrations. Further stepwise passages were done when indicated. 318 
After passages bacteria were collected and macrodilution MIC was determined. An 319 
identical methodology was used for selection of chlorhexidine reduced-susceptible 320 
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mutants of strains COL, MRSA134947 and MRSA128822, showing an initial 321 
chlorhexidine MIC of 2, 4 and 8 µg/ml, respectively. 322 
Antimicrobial susceptibility testing. The bacterial inoculum suspension was 323 
prepared by selecting several colonies from overnight growth (16Ð24 h of incubation) 324 
on Columbia Agar plates with a cotton swab and suspending the colonies in sterile 325 
saline (0.85% NaCl w/v in water) to the density of a 0.5 McFarland standard, 326 
corresponding to 3-4 x 10
8
 CFU/ml. The inoculum was spread over the entire surface of 327 
the MuellerÐHinton agar plate by swabbing in three directions, and the plates were 328 
incubated in a humid atmosphere at 35 ± 1¡C for 18 ± 2 h. Antibiotic resistance profiles 329 
were tested using disc diffusion assays according to EUCAST methods. 330 
Genome sequencing. High-throughput sequencing was used to sequence the 331 
genomes of all isolates. Genomic DNA from each isolate was purified by using DNeasy 332 
columns (Qiagen), and then sequenced on the Illumina HiSeq 2500 (Illumina, San 333 
Diego, CA, USA) using 100 bases paired-ends and barcodes according to the Nextera 334 
XT kit (Illumina). Read sequence quality was assessed with the Fastqc program 335 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and filtered using the 336 
fastq-mcf program (Ea-utils: http://code.google.com/p/ea-utils). Genome assembly was 337 
performed using the Edena v3 assembler (32). Assembled genomes were annotated 338 
using the Prokka v1.10 program (33). The phylogenetic relationships of isolates were 339 
investigated by genomic single-nucleotide polymorphism (SNP)-based analysis using 340 
the Parsnp v1.0 program (34). The proteome comparison of all isolates was performed 341 
using the ÒCGView Comparison ToolÓ program (35). The BlastP analysis was used to 342 
detect non-synonymous mutations. 343 
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Table 1 : Polyhexanide and chlorhexidine resistant profiles of in vitro selected antiseptic mutants 479 
 
Strain 
Antiseptic 
selection 
Number of 
passages 
Polyhexanide
a
 
MIC (µg/ml) 
Chlorhexidine
a
  
MIC (µg/ml) 
COL  -   0.5 2 
COL P3 Polyhexanide 3 2 2 
COL P5 Polyhexanide 5 4 2 
134947  -   1 4 
134947 P6 Polyhexanide 6 8 4 
128822  -   1 8 
128822 P6 
b
 Polyhexanide 6 1 8 
COL  -   0.5 2 
COL P10 Chlorhexidine 10 0.5 8 
COL P7 Chlorhexidine 7 0.5 8 
134947  -   1 4 
134947 P10 Chlorhexidine 10 1 8 
128822  -   1 8 
128822 P10 Chlorhexidine 10 1 8 
a
 Polyhexanide and chlorhexidine MIC are measured by macrodilution method   
b
 Selection of Polyhexanide step-wise mutants was impossible with this strain    
 480 
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Table 2 : Antibiotic resistant profiles and single nucleotide polymorphisms present in MRSA antiseptic selected mutants compared to their corresponding wild-type strains 481 
 482 
a
 Antibiotic susceptibility was measured by disc diffusion assays for all antibiotics except vancomycin, teicoplanin and daptomycin (D corresponds to diameter size measurement; 483 
EUCAST ciprofloxacin susceptible diameter = 19-20). For vancomycin, teicoplanin and daptomycin, MIC values were determined by Etest assays. EUCAST susceptibility 484 
ďƌĞĂŬƉŽŝŶƚƐ ĨŽƌ ǀĂŶĐŽŵǇĐŝŶ ч ? ?  ƚĞŝĐŽƉůĂŶŝŶ ч ? ? ĚĂƉƚŽŵǇĐŝŶ ч ? ? ŚĂŶŐĞƐ ŝŶ ĂŶƚŝďŝŽƚŝĐ ƌĞƐŝƐƚĂŶĐĞ ƉĂƚƚĞƌŶ  ĐŽŵƉĂred to wild-type strains are shown in bold. Pen=penicillin; 485 
Oxa=oxacillin; AC=amoxicillin-clavulanate; Cef=cefoxitine; Cip=ciprofloxacin; Cli=clindamycin; Ery=erythromycin; Gen= gentamicin; Van=vancomycin; Tei=teicoplanin; 486 
Dap=daptomycin.487 
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Table 3 : Chlorhexidine and Polyhexanide MIC values of 54 MRSA clinical strains isolated before and 488 
after Polyhexanide patient decolonization. 489 
  MIC (µg/ml)   MIC (µg/ml) 
Strain number 
(Day 0)
*
 
Chlorhexidine    Polyhexanide  
Strain number 
(Day 28)
*
 
 Chlorhexidine  Polyhexanide 
1 4 0.5 1a 4 0.5 
2 < 0.5 0.5 2a 1 / 0.5  1 
3 4 0.5 3a 4 1 
4 < 0.5 0.5 4a < 0.5 0.5 
5 4 0.25 5a  2 / 4 0.5 
6 4 0.5 6a 2 0.5 
7 4 0.5 7a 4 0.5 
8 1 0.5 8a 1 0.5 
9 < 0.5 0.5 9a < 0.5 0.5 
10 4 0.5 10a 4 0.5 
11 4 0.5 11a 1 0.5 
12 4 0.25 12a 4 0.5 
13 4 1 13a < 0.5 0.5 
14 4 0.5 14a 2 1 
15 1 1 15a 4 0.5 
16 2 0.5-1 16a 4 0.5 
17 < 0.5 1 17a < 0.5 0.5 
18 4 0.5 18a 4 0.25 
19 4 0.5 19a 4 0.5 
20 2 0.5 20a 2 0.5 
21 2 0.25 21a 2 0.25 
22 < 0.5 0.5 22a 1 1 
23 2 1 23a 1 1 
24 4 0.5 24a 4 0.5 
25 4 0.5 25a 1 0.5 
26 4 0.5 26a 4 0.5 
27 2 1 27a 4 0.25 
* MRSA clinical strains isolated prior to Polyhexanide decolonization (Day 0) or after 28 days of 
polyhexanide treatment (D 28) 
(a) denoted MRSA Day 28 bacteria clonally-related to Day 0 bacteria, isolated from the same patient 
Bold font is used for pairs of strains showing the most important changes 490 
